Format

Send to

Choose Destination
Dermatol Surg. 2015 Jun;41(6):693-701. doi: 10.1097/DSS.0000000000000340.

Evolution of Facial Aesthetic Treatment Over Five or More Years: A Retrospective Cross-sectional Analysis of Continuous OnabotulinumtoxinA Treatment.

Author information

1
*Carruthers Clinical Research, Vancouver, Canada; †Sadick Research Group, New York, New York; ‡Dr. Brandt Dermatology Associates, Coral Gables, Florida; §Hospital Do Servidor Publico Municipal, Sao Paulo, Brazil; ‖Aesthetic Eyelid Plastic Surgery, Boca Raton, Florida; ¶Monash University, Clayton, Victoria, Australia; #Cannes Private Clinic, Cannes, France; **Niagara Falls Dermatology and Skin Care Center, Niagara Falls, Canada; ††Allergan, Inc., Irvine, California; ‡‡Peloton Advantage, Parsippany, New Jersey.

Abstract

BACKGROUND:

Little information exists on how facial aesthetic treatments are incorporated into aesthetic regimens.

OBJECTIVE:

Assess the evolution of facial aesthetic treatments in patients receiving long-term continuous onabotulinumtoxinA treatment.

METHODS:

This international retrospective chart review included patients with ≥5 years of continuous onabotulinumtoxinA treatments including ≥1 glabellar lines treatment/year. Charts were reviewed for facial areas treated, number of treatments, doses/treatment visit, concomitant aesthetic procedures, and onabotulinumtoxinA-related adverse events.

RESULTS:

Data were collected from 5,112 onabotulinumtoxinA treatment sessions for 194 patients over an average of 9.1 years. Dosing was relatively stable over time; however, interinjection intervals increased. Glabellar lines' treatment temporally preceded crow's feet lines and forehead lines' treatment. A majority of patients (85%) also received treatment with fillers. Cumulative increases in onabotulinumtoxinA treatments occurred over time and by facial area corresponding with increases in treatments with injectable fillers, energy-based devices, and prescription topical creams. The longer the patients were treated, the younger they perceived themselves to look. Rates of adverse events were low.

CONCLUSION:

OnabotulinumtoxinA treatment evolved over time, coinciding with growth of the facial aesthetics market. Additional treatment modalities were added as complements to onabotulinumtoxinA. Long-term continuous onabotulinumtoxinA injections are an important component of contemporary facial aesthetic treatment regimens.

PMID:
25973559
DOI:
10.1097/DSS.0000000000000340
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center